WAKE FOREST, North Carolina and ADELAIDE, Australia, Oct. 31, 2024 (GLOBE NEWSWIRE) — Avance Clinical, a leading global full-service contract research organization (or CRO) renowned for responsiveness and superior quality of its clinical research services, proudly announces the signing of three major MOUs with key Korean clinical sites at the KoNECT 2024 conference.
Yvonne Lungershausen, CEO of Avance Clinical, and Jessica Han, Regional Director of the Asia branch, attended the KoNECT conference alongside the three clinical sites selected for signing these partnerships. This event marks an important milestone in the company’s strategic development in the Asia-Pacific region.
Avance Clinical is a mid-sized CRO with a proven track record of rapidly implementing high-performance clinical programs. It has an excellent reputation among US-based biotech companies, which currently make up over 80% of its portfolio.
“These new MOUs reinforce our mission to provide world-class services to international clients in the biotechnology sector. » observes Ms. Lungershausen. He continued: “As Avance Clinical continues to expand its global footprint, these partnerships with respected institutions will only enhance our ability to provide flexible, efficient and high-quality clinical trial services in the Asia-Pacific region. »
Jessica Han, based in Seoul, adds: “Due to its highly sophisticated healthcare infrastructure and regulatory framework, South Korea is an ideal environment for clinical trials. In addition to consolidating our collaborations with key institutions, the signing of these MOUs will allow us to provide our clients with access to high-quality clinical trial sites, but also to regional patient populations in complete transparency. . We look forward to building closer ties and driving growth in Asia. »
The memorandums of understanding were signed with:
The university medical center CHA University Bundang Medical Centera 1,000-bed, state-of-the-art hospital with a focus on patient care, research and education. Considered a research-oriented hospital, the facility is committed to providing a state-of-the-art environment and infrastructure to support the latest studies and most advanced medical technologies. This partnership with Avance Clinical will strengthen its reach and influence on the development of care on a global scale.
It was signed on October 28, 2024
Young-Sang Kim, Director of the University Hospital Clinical Trials Center CHA Global Clinical Trials Center (CHA University Bundang Medical Center) did not fail to express its enthusiasm for this collaboration: “This partnership with Avance Clinical represents a valuable opportunity to expand our expertise in clinical trials, particularly in the area of early phase research. We are confident that this collaboration will strengthen our capabilities, while also enabling us to deliver cutting-edge therapeutic solutions relevant to patients globally. »
Korea University School of Medicine, Korea University Medicine, located in Seoul, is a leading academic and medical institution recognized for its extensive clinical trial capabilities. This partnership aims to accelerate clinical research prospects, leveraging Korea University Medicine’s expertise to drive the development of innovative therapies.
It was signed on October 29, 2024
Hak Jun Kim, Chairman of Medical Research and Enterprise Foundation of Korea University Medicinewas optimistic about this partnership: “We are delighted to collaborate with Avance Clinical, a world-class CRO. This MOU marks an important starting point to further strengthen our unique strengths. We want to maintain a close relationship in order to play a key role in the field of clinical trials. »
The clinical trial center at Dong-A University Hospital, located in Busan, is renowned for its comprehensive clinical trial infrastructure and experienced research teams. The collaboration with Dong-A University aims to deepen research ties, particularly in early-phase clinical trials, to provide new options for customers interested in developing innovative treatments across multiple therapeutic areas.
It was signed on October 30, 2024
Sung Yong Oh, Director of clinical trial center of Dong-A University Hospital expressed confidence in the new collaboration, saying: “This partnership with Avance Clinical marks a turning point for us. By cooperating, we can further improve our research infrastructure and contribute significantly to global healthcare innovations. We are confident that this collaboration will accelerate the development of advanced medical technologies and treatments. »
The signing of the memorandums of understanding and Avance Clinical’s participation in KoNECT reflect the company’s determination to expand its presence around the world. KoNECT 2024, jointly organized by the Korea National Enterprise for Clinical Trials (or KoNECT) and the Ministry of Health and Welfare (MOHW), is a premier event that enables leaders to opinion and industry professionals to discuss innovations in clinical trials in the Asia-Pacific region.
About Avance Clinical
Avance Clinical is a leading contract research organization (or CRO) providing faster, more flexible and higher quality clinical trial services to biotechnology companies. Avance Clinical is Australia’s largest and most comprehensive CRO, delivering quality clinical trials with globally accepted data, supporting international biotechnology companies in Australia, New Zealand, Asia, United States and Europe. Backed by 30 years of experience, Avance Clinical provides clients with comprehensive clinical research services, specializing in early to late phase clinical trials. With experience in more than 250 indications, ORC can provide world-class results and internationally recognized high-quality data for evaluation by the FDA and AEM.
The company was distinguished by the Frost & Sullivan Global & APAC CRO Market Leadership & Customer Value Leadership Awards over the last five years. Avance Clinical provides services from preclinical to late-stage clinical trials, leveraging significant government grants Australian that can reach 43,5 %and regulatory processes ensuring a rapid launch.
By relying on cutting-edge technologies such as Medidata, Oracle and MedrioAvance Clinical ensures its customers have the most efficient testing processes and provides them with high-quality data for analysis by the FDA and AEM.
For more information, visit the website Avance Clinical.
To find out more:
A photo attached to this press release is available at the following address:
